Antibacterial resistance is one of the greatest threats to human health. The development of
new therapeutics against bacterial pathogens has slowed drastically since the approvals of …

The problem of antibiotic resistance is on the rise, with multidrug-resistant strains emerging
even to the last resort antibiotics. The drug discovery process is often stalled by stringent cut …

Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat
serious Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including …

Resistance of Acinetobacter baumannii to multiple clinically important antimicrobials has
increased to very high rates in Greece, rendering most of them obsolete. The aim of this …

Gram-negative bacterial resistance to antimicrobials has had an exponential increase at a
global level during the last decades and represent an everyday challenge, especially for the …

A total of 43 A. baumannii strains, isolated from 43 patients affected by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and by bacterial sepsis, were analyzed …

Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination
in late-stage development for the treatment of Acinetobacter infections, including those …

ABSTRACT Objectives Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly
strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health …

Carbapenem‐resistant Acinetobacter baumannii (CRAB) is a difficult‐to‐treat nosocomial
pathogen responsible for significant morbidity and mortality. Sulbactam‐durlobactam (SUL …

Infections caused by Acinetobacter baumannii are increasingly multidrug resistant and
associated with high rates of morbidity and mortality. Sulbactam is a β-lactamase inhibitor …